53 results about "Rosacea" patented technology

The invention provides a facial skin flaw enhancement method based on a Lab color space. The method comprises the following steps: firstly, acquiring an RGB face image and converting the RGB face image into a CIE Lab color space with uniform perception; then, performing differentiation treatment according to the manually selected skin flaw type: for the vascular flaw, extracting statistical characteristics of a component and driving adaptive nonlinear transformation, and generating a grey-scale map which highlights the red flaw; for pigment flaws, nonlinear transformation is carried out on the component L, and then collaborative linear weighting and feature amplification are carried out on the component L, the component a and the component b, so that a grey-scale map with highlighted pigment spots is generated. And finally, coloring the grey-scale map in the Lab color space through adjustable parameters to generate a high-contrast color enhanced image. The method overcomes the dependence on hardware and training data in the prior art, can clearly and adaptively enhance various flaws such as acnes, couperose streaks and color spots, shows robustness under different illumination, and can be widely applied to clinical beauty, later photography and real-time video processing.

This invention discloses an acne-repairing and repairing composition for promoting microcirculation in acne-prone and sensitive skin, and its application, relating to the field of cosmetic technology. The invention provides an acne-repairing and repairing composition comprising the following components in parts by weight: Vitamin K2 0.05-1 parts, Swertia japonica extract 0.1-1.5 parts, Guaiac extract 0.1-2 parts, Cerium oxide microspheres 0.005-0.1 parts, and Morus alba root extract 0.5-5 parts; wherein the average particle size of the Cerium oxide microspheres is 0.2-3 μm, and the Cerium oxide microspheres contain Ce. 3+ The Ce 3+ The molar percentage of cerium oxide microspheres is 30-38%. This invention provides an acne-repairing composition. In actual experiments, the inventors discovered that when vitamin K2, Swertia trifasciata extract, Guaiac extract, cerium oxide microspheres, and mulberry root extract are present simultaneously, the five components can synergistically work together to reduce skin roughness and improve rosacea and acne.

The invention discloses a SerpinB3 inhibitor and an application of the SerpinB3 inhibitor. The phloretin can be used as the SerpinB3 inhibitor for the first time, can effectively relieve the symptoms of the rosacea and the psoriasis at the same time, and is used for preparing related drugs for treating inflammatory skin diseases such as the rosacea and the psoriasis. The invention provides a certain theoretical basis for research and development of related treatment products for inflammatory skin diseases such as rosacea or psoriasis.

Provided herein are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cat's claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.

The present invention relates to a cosmetic composition, advantageously an eco-biological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the general formula (I) in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an alpha-amino acid chosen from the group consisting of phenylalanine, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The present invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating cutaneous vascular hyperproliferation and / or cutaneous inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combating these pathologies.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

1. Name of the product subject to this design: Laser Therapy Machine (YL900-2024). 2. Application of this design: for use in the medical aesthetics industry for skin rejuvenation, freckle removal, pigmentation reduction, and treatment of rosacea. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. The bottom surface of this product is a part that is not easily seen or cannot be seen during use, so the bottom view is omitted.

A method of topically applying to skin a composition comprising a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus is disclosed.

This invention provides the application of ginsenoside Rh1 in the treatment of inflammatory skin diseases, belonging to the field of biomedical technology. It is the first to demonstrate that ginsenoside Rh1 inhibits AQP3 expression by activating the oxidative phosphorylation pathway and regulating cellular homeostasis, thereby inhibiting AQP3 gene transcription and / or expression. As a novel AQP3 inhibitor, it downregulates AQP3 protein expression levels in an animal model of rosacea. This provides a novel strategy and drug candidate for targeted therapy of rosacea and other AQP3-related inflammatory skin diseases.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The invention relates to application of cembratrienediol in preparation of a medicine for preventing and treating rosacea, and belongs to the technical field of biological medicine. The invention provides an application of cembratrienediol in preparation of a medicine for preventing / or treating rosacea. The cembratrienediol can obviously improve erythema and inflammation of an injection area of a rosacea mouse model for a long time and a short time; the skin tissue pathological inflammation of the rosacea mouse model can be obviously relieved (including the thickening of the skin epidermis of the rosacea mouse model, the inflammatory cell infiltration of the skin tissue of the rosacea mouse model and the capillary hyperplasia of the skin tissue of the rosacea mouse model); skin inflammation of a rosacea patient can be remarkably relieved (including relieving pain of the skin of the rosacea patient and relieving the red and swollen degree of the skin of the rosacea patient), and skin injuries of the rosacea patient can be remarkably improved (including improving papules and pustules of the skin of the rosacea patient).

The present invention relates to a method for inducing, stimulating, and / or promoting the healing of a wound or damaged skin area, comprising topically treating a subject's skin surrounding the wound or damaged skin area with conditioned medium derived from a culture of umbilical cord mesenchymal stem cells. Similarly, the present invention relates to a method for preventing the formation and / or recurrence of wounds or damaged skin areas in a subject at risk of developing wounds or damaged skin areas, comprising topically treating the subject's skin with conditioned medium derived from a culture of umbilical cord mesenchymal stem cells. Furthermore, the present invention relates to a method for treating skin damage caused by rosacea, psoriasis, eczema, dermatitis, topical steroid withdrawal syndrome, epidermolysis bullosa, or fragile skin, comprising topically treating a subject's skin surrounding the wound or damaged skin area to be treated with conditioned medium derived from a culture of umbilical cord mesenchymal stem cells. The present invention is also directed to the conditioned medium, uses thereof, compositions comprising it, methods for producing the conditioned medium, and uses of these compositions.

The invention discloses a pharmaceutical composition for rosacea as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is prepared from radix bupleuri, radix scutellariae, cortex cinnamomi, honey-fried licorice root, rhizoma zingiberis, radix trichosanthis, nacre mother of pearl, oyster, cornu bubali and cortex moutan. The pharmaceutical composition obtains a satisfactory clinical curative effect in clinical treatment, has a remarkable clinical curative effect and small side effects when being used for treating and / or preventing neurogenic rosacea, and has a wide market and application prospect.

To provide a composition for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals.SOLUTION: There is provided a composition comprising benzalkonium halide; didecyldimethylammonium halide; polyhexamethylene biguanide salt; bronopol; and p-chloro-m-cresol.SELECTED DRAWING: None

The invention discloses preparation and application of a double-enzyme-driven stage response type external preparation, which comprises the following steps: preparing drug-loaded hyaluronic acid (HA) microspheres, namely constructing emodin (EMD)-loaded hyaluronic acid microspheres (EMD-HA microspheres) for a responsive traditional Chinese medicine external preparation; preparation of hyaluronidase (HAase) gelatin microspheres; preparing a medicine-containing ointment substrate; and carrying out magnetic stirring or mechanical homogeneous stirring on the obtained EMD-HA microspheres, HAase gelatin microspheres and an ointment matrix for 30 minutes at room temperature on the basis of a dosage ratio, so that the microspheres are fully and uniformly dispersed in the ointment matrix, thereby obtaining the dual-enzyme driven stimulus-responsive external preparation. According to the preparation disclosed by the invention, 'targeted response 'treatment aiming at different stages of rosacea is realized; the convenience and compliance of treatment are improved, and meanwhile, individualized precise treatment for rosacea is realized.

The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the amelioration of symptoms associated with rosacea-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus helveticus, (ii) Lactobacillus plantarum, (iii) Bifidobacterium longum, and (iii) Streptococcus thermophilus; and (b) at least one plant-based, antioxidant-rich source of fiber.

The invention discloses application of vicenin-2 in preparation of a pharmaceutical preparation for treating and / or preventing rosacea, and belongs to the technical field of biological medicines. Vitin-2 blocks conduction of an IL-17 signal channel through targeted regulation and control of an IL-17RA / ACT1 / TRAF6 axis, further inhibits activation of an NF-kappa B signal channel, reduces levels of inflammatory factors TNF alpha, IL-6, IL-1beta and IL-8 induced by LL-37, inhibits expression of mRNA of TNF alpha, IL-6 and IL-1beta, inhibits phosphorylation of key protein of the channel, reduces protein expression levels of MMP1 and MMP3 at the downstream of the channel, and further inhibits activation of an NF-kappa B signal channel. Further, the effect of resisting the acne rosacea inflammatory response is achieved. Besides, the external vicenin-2 solution can relieve back erythema and angiotelectasis of a rosacea-like mouse model, pathological tissue section HE staining shows that the external vicenin-2 solution can relieve LL-37-induced skin inflammation infiltration, and the weight of a mouse is not obviously reduced compared with that before treatment; and the skin erythema and scales of mice are not generated by external use of the vicainin-2 solution.

The invention relates to the field of biological medicine, in particular to application of an IL7R inhibitor in preparation of a medicine for treating rosacea. The IL7R inhibitor comprises preparations for inhibiting the IL7R at the gene level and the protein level, the preparations for inhibiting the IL7R at the gene level comprise shRNA, siRNA, dsRNA, miRNA, cDNA and antisense RNA / DNA, and the preparations for inhibiting the IL7R at the protein level comprise small molecule compounds, peptides and antibodies. It is found for the first time that the targeted IL7R has a remarkable treatment effect on rosacea, the recurrence rate can be effectively reduced, and the skin lesion degree can be relieved. The discovery not only opens up a new direction for fundamental research of rosacea, but also provides a brand-new and breakthrough solution for clinical treatment of rosacea, and is expected to bring a more durable and stable treatment effect for patients.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

The application provides a composition for regulating intestinal flora to intervene in rose acne, comprising oral preparations and skin external preparations thereof, and relates to the technical field of biological medicines.The composition is composed of a prebiotic component inulin or a dandelion water extract containing inulin, and a humanized rhamnosus strain or a bacterial body lysate, culture supernatant or metabolite thereof.The composition can promote the proliferation of the humanized rhamnosus in the intestinal tract after being taken orally, significantly enhance the tryptophan metabolism capacity of the humanized rhamnosus, and improve the intestinal indole-3-lactic acid level;ILA enters blood through the intestinal-skin axis, and acts on the skin keratinocyte aromatic receptor, so that the immune homeostasis is systematically regulated and the skin inflammation is relieved.Experiments prove that the composition has a significant prevention and intervention effect on a rose acne model of mice induced by LL-37, can reduce the erythema area, and relieve the inflammatory symptoms.

The invention provides a composition comprising oleanolic acid and the salts, prodrug and solvates thereof; and one or more compounds selected from the following group: ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid and tyramine, and the salts, prodrugs and solvates thereof. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea.

The invention belongs to the technical field of acne rosacea treatment, and discloses a preparation method and application of a composition for treating acne rosacea, the composition for treating acne rosacea contains a moutan bark extract and a coptis chinensis extract, and also contains a lucid ganoderma extract, a cinnamon extract, paeoniflorin and syringic acid. The inflammatory response of rosacea is closely related to the expression of two core inflammatory factors, namely TNF-alpha and TLR4, and the invention consciously aims at the TLR4-TNF-alpha inflammatory axis multi-target design, inhibits the expression of TLR4 and TNF-alpha, and blocks the'start-amplification 'chain of inflammation, thereby inhibiting the recurrence of inflammation. In addition, the composition for treating rosacea provided by the invention can also improve capillary dysfunction, effectively inhibit microbial growth, and prevent and treat rosacea from multiple dimensions.

The application relates to application of cedrene diol in preparation of medicines for preventing and treating rosacea, and belongs to the technical field of biological medicines. The application provides application of cedrene diol in preparation of medicines for preventing and / or treating rosacea. The cedrene diol can significantly improve redness and inflammation of an injection area of a rosacea mouse model in long and short terms, can significantly relieve skin histopathological inflammation of the rosacea mouse model (including improving thickening of skin epidermis of the rosacea mouse model, reducing inflammatory cell infiltration of skin tissue of the rosacea mouse model, and reducing capillary proliferation of skin tissue of the rosacea mouse model), can significantly reduce skin inflammation of a rosacea patient (including reducing pain of the skin of the rosacea patient and relieving redness of the skin of the rosacea patient), and can significantly improve skin damage of the rosacea patient (including improving papules and pustules of the skin of the rosacea patient).

The invention relates to the technical field of medicine, in particular to application of N-ethyl maleimide in inflammatory dermatosis, by adopting an LL-37-induced mouse rosacea model, experiments prove that NEM can directly and effectively inhibit inflammatory response by inhibiting glycerophospholipid metabolism and regulating expression of related genes such as keratinocytes and T lymphocytes, so that the inflammatory response is effectively inhibited, and the inflammatory response is inhibited. The compound can improve mouse rosacea-like rash, has no obvious cytotoxicity, can be used as a candidate compound, is used for developing a glycerophospholipid metabolism inhibitor, and is used for treating skin inflammatory diseases related to glycerophospholipid metabolism, such as rosacea and psoriasis. By utilizing multiple experimental means such as transcriptomics sequencing, histopathologic examination, reverse transcription real-time fluorescent quantitative PCR (RT-qPCR) and the like, it is proved for the first time that N-ethyl maleimide improves mouse rosacea by inhibiting glycerophospholipid metabolism.

A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.

The application belongs to the technical field of drug research and development, and particularly relates to a compound, a preparation method and application of the compound as an agonist of orphan receptor GPR99. The application first discovers and identifies a small-molecule compound capable of specifically activating the orphan receptor GPR99, and systematically clarifies the mechanism of the small-molecule compound in the regulation of vascular smooth muscle cell (VSMC) contraction and the improvement of pathological vascular dilation. The discovery not only fills the blank of GPR99 agonists in the field of treatment of rosacea, but also provides a new molecular target and a drug research and development direction for precise treatment of diseases related to abnormal vascular function.

The present invention relates to a therapeutic device that emits multi-frequency ultrasound, and more specifically, to a skin disease treatment device capable of alternately or selectively emitting ultrasound of multiple frequency bands within the range of 0.6 MHz to 20 MHz from an ultrasound transducer when performing ultrasound treatment using an ultrasound transducer in contact with the surface of human skin, particularly the skin of the face. Unlike conventional ultrasound transducers that emit only ultrasound of a single frequency band, a single ultrasound transducer is used that alternately or selectively emits ultrasound of multiple frequency bands within the range of 0.6 MHz to 20 MHz. Specifically, a high-frequency generating ultrasound transducer that generates a waveform with a large amplitude and a short period (high frequency band), a low-frequency generating ultrasound transducer that generates a waveform with a relatively smaller amplitude and longer period than the high-frequency generating ultrasound transducer (low frequency band), and a medium-frequency generating ultrasound transducer in the intermediate frequency band can be replaced by a single ultrasound transducer. Since high-frequency, medium-frequency, and low-frequency ultrasounds can be selectively or alternately generated, this device is suitable for specialized skin hospitals or skin massage clinics. Since it is possible to perform skin treatment with optimal ultrasound using a minimal number of ultrasound devices without having to equip a business with various types of ultrasound devices, individuals, specialized skin clinics, or specialized skin massage businesses can minimize the purchase cost of ultrasound devices and reduce maintenance costs. Additionally, by generating high-frequency, medium-frequency, and low-frequency ultrasounds tailored to the lesions, it can have an excellent effect in treating lesions that have been difficult to treat until now, such as intractable rosacea and acne.

The invention relates to a quercetin-loaded cellulose nanocrystal and a preparation method and application thereof, and the method comprises the following steps: S1, preparing an ethanol solution of quercetin with the concentration of 10-30 mg / mL; s2, preparing a Tween aqueous solution according to the proportion of 1-3% (w / v); s3, adding the ethanol solution of the quercetin into the Tween aqueous solution while stirring, wherein the volume ratio of the ethanol solution of the quercetin to the Tween aqueous solution is (0.5-1.5): (200-300); s4, adding 0.25-1% (w / v) of cellulose nanocrystal suspension into the system obtained in the step S3, and continuously stirring and homogenizing to obtain a mixed solution containing quercetin-loaded cellulose nanocrystals (QL-CNC); the volume ratio of the cellulose nanocrystal suspension to the ethanol solution of quercetin is (200-300): (0.5-1.5). The obtained QL-CNC has good biological safety, the rosacea treatment efficiency is improved, and meanwhile, a novel nano treatment strategy is provided for rosacea and other oxidative stress related inflammatory skin diseases.

The present application relates to the field of biological medicine, and particularly relates to application of IL7R inhibitor in preparation of a drug for treating rosacea. The IL7R inhibitor includes preparations for inhibiting the IL7R at the gene level and the protein level, the preparation for inhibiting the IL7R at the gene level is shRNA, siRNA, dsRNA, miRNA, cDNA, antisense RNA / DNA, and the preparation for inhibiting the IL7R at the protein level is a small molecule compound, a peptide and an antibody. It is found for the first time that targeting IL7R has a significant therapeutic effect on rosacea, can effectively reduce the recurrence rate and reduce the degree of skin lesions. This finding not only opens up a new direction for the basic research of rosacea, but also provides a brand-new and breakthrough solution for the clinical treatment of rosacea, and is expected to bring more persistent and stable therapeutic effect for patients.